Citius Pharmaceuticals, Inc. — FY2017 Form 10-K
Reporting period: Fiscal year ended September 30, 2017; this is an annual report, not a standalone fourth-quarter report. Citius is a clinical-stage specialty pharmaceutical company developing Mino-Lok for catheter-related bloodstream infections and Hydro-Lido for hemorrhoids. The company reported no revenue.
Financial performance and position
| Metric | FY2017 / September 30, 2017 | Prior comparable period |
|---|---|---|
| Revenue | $0 | $0 in FY2016 |
| Research and development expense | $2.94 million | $2.93 million in FY2016 |
| General and administrative expense | $6.06 million | $3.78 million in FY2016 |
| Total operating expenses / operating loss | $9.99 million / $(9.99) million | $7.45 million / $(7.45) million in FY2016 |
| Net loss | $(10.38) million; $(1.89) per share | $(8.30) million; $(2.29) per share in FY2016 |
| Net cash used in operations | $(7.97) million | $(5.90) million in FY2016 |
| Cash and cash equivalents | $3.20 million | $0.29 million |
| Working capital | $0.96 million positive, based on reported current assets and liabilities | $4.29 million deficit, based on reported current assets and liabilities |
| Notes payable | $0.17 million, all current and related-party | $0.67 million |
| Total assets / stockholders’ equity | $24.42 million / $21.95 million | $21.95 million / $16.77 million |
Margins are not meaningful because the company had no revenue. Assets included $19.4 million of in-process research and development and $1.59 million of goodwill. The filing reports an accumulated deficit of $27.72 million.
Changes and financing
- Net loss increased $2.09 million year over year. Higher G&A expense—partly reflecting a full year of costs following the 2016 LMB acquisition—and higher interest expense were the main drivers; the change in warrant revaluation partly offset these increases.
- Operating cash use rose by $2.07 million. The company financed operations through equity and related-party borrowing; FY2017 financing cash inflows were $10.88 million.
- In August 2017, Citius completed a public offering with gross proceeds of approximately $6.80 million and converted approximately $4.79 million of chairman-related principal and accrued interest into common stock. The conversions reduced reported debt but added shares; the offering and associated warrants also created potential dilution.
- The company completed a 1-for-15 reverse stock split in June 2017. It reported 8,345,844 shares outstanding at fiscal year-end and 8,423,391 at December 1, 2017.
Pipeline, outlook, and risks
- Mino-Lok: The FDA provided feedback in August 2017 supporting an amended Phase 3 design using an active standard-of-care control rather than saline/heparin placebo. The company expected enrollment to begin in fourth-quarter 2017. FDA Fast Track designation was announced in October 2017, after fiscal year-end. Earlier Phase 2b and international study results cited by the company were encouraging, but do not establish approval or commercial success.
- Hydro-Lido: The company planned to reformulate the product and develop updated evaluation tools before starting a planned 300-patient Phase 2b study. Estimated study cost was approximately $4 million, with an expected duration of about one year; timing depended on formulation and funding.
- Funding and going concern: The auditor highlighted substantial doubt about Citius’s ability to continue as a going concern. Management said available capital was expected to support operations for about six months from September 30, 2017, and that additional financing was needed; there was no assurance it could be obtained on acceptable terms or in time. The filing’s financial statements show positive working capital of $0.96 million, while the auditor’s going-concern discussion refers to a working-capital deficit—an apparent inconsistency to clarify.
- Controls and execution: Management concluded disclosure controls and internal control over financial reporting were ineffective, citing undocumented procedures, reliance on consultants for financial reporting, and insufficient segregation of duties. The company had seven employees and relied on outside manufacturers and clinical-service providers.
- Other risks and contingencies: Both candidates remained subject to clinical, regulatory, manufacturing, reimbursement, commercialization, intellectual-property, and financing risks. Citius reported no material pending litigation. In November 2017, it agreed to pay Aegis $100,000 and issue 60,000 restricted shares to obtain release from an underwriting right of first refusal.
Investor facts to verify
- Current cash runway, subsequent financing, and actual spending against the stated six-month funding horizon.
- Whether Mino-Lok Phase 3 enrollment began as planned, the final protocol and comparator, and the milestones and costs required to complete the trial.
- Hydro-Lido reformulation progress, Phase 2b start date, and funding availability for the estimated $4 million study.
- Remediation of the disclosed internal-control material weaknesses and resolution of the filing’s working-capital inconsistency.
- Potential dilution from outstanding warrants, options, and other equity-linked securities, and the terms of any further related-party financing.